Jeff M. Milunsky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jeff M. Milunsky has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Thomas A. Maher
Center for Human Genetics, Boston University School of Medicine, Boston, Massachusetts
6 shared publications - Ying S. Zou
Department of Pathology Johns Hopkins University School of Medicine Baltimore Maryland USA
5 shared publications Aubrey Milunsky
Center for Human Genetics and the Department of Pediatrics, Boston University School of Medicine, Boston, MA 02118
4 shared publicationsGeping Zhao
Center for Human Genetics, Boston University School of Medicine, Boston, Massachusetts
4 shared publicationsTom A. Maher
Center for Human Genetics, Boston University School of Medicine, Boston, Massachusetts
4 shared publicationsAngela E. Lin
Genetics Unit, MassGeneral Hospital for Children, Boston, Massachusetts
3 shared publications
Latest Publications
- 10 June 2011
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 155 (7) , 1740-1744
Partial trisomy 8 mosaicism due to a pseudoisodicentric chromosome 8
Chromosome 8 is the largest autosome in which mosaic trisomy is compatible with life. Constitutional trisomy 8 (T8) is estimated to occur in approximately 0.1% of all recognized pregnancies. The estimated frequency of trisomy 8 mosaicism (T8M), also known as Warkany syndrome, is about 1/25,000 to 50,000 liveborns, and is found to be more prevalent in males than females, 5:1. T8M is known to demonstrate extreme clinical variability affecting multiple systems including central nervous, ocular, cardiac, gastrointestinal, genitourinary, and musculoskeletal. There appears to be little correlation between the level of mosaicism and the extent of the clinical phenotype. Additionally, the exact mechanism that causes the severity of phenotype in patients with T8M remains unknown. We report on a mildly dysmorphic male patient with partial low‐level T8M due to a pseudoisodicentric chromosome 8 with normal 6.0 SNP microarray and high resolution chromosome analyses in lymphocytes. The aneuploidy was detected in fibroblasts and confirmed by FISH in lymphocytes. This report elaborates further the clinical variability seen in trisomy 8 mosaicism.
- 10 June 2011
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 155 (7) , 1740-1744
Partial trisomy 8 mosaicism due to a pseudoisodicentric chromosome 8
Chromosome 8 is the largest autosome in which mosaic trisomy is compatible with life. Constitutional trisomy 8 (T8) is estimated to occur in approximately 0.1% of all recognized pregnancies. The estimated frequency of trisomy 8 mosaicism (T8M), also known as Warkany syndrome, is about 1/25,000 to 50,000 liveborns, and is found to be more prevalent in males than females, 5:1. T8M is known to demonstrate extreme clinical variability affecting multiple systems including central nervous, ocular, cardiac, gastrointestinal, genitourinary, and musculoskeletal. There appears to be little correlation between the level of mosaicism and the extent of the clinical phenotype. Additionally, the exact mechanism that causes the severity of phenotype in patients with T8M remains unknown. We report on a mildly dysmorphic male patient with partial low‐level T8M due to a pseudoisodicentric chromosome 8 with normal 6.0 SNP microarray and high resolution chromosome analyses in lymphocytes. The aneuploidy was detected in fibroblasts and confirmed by FISH in lymphocytes. This report elaborates further the clinical variability seen in trisomy 8 mosaicism.
- 28 December 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 155 (1) , 22-32
Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome
Branchio‐oculo‐facial syndrome (BOFS; OMIM#113620) is a rare autosomal dominant craniofacial disorder with variable expression. Major features include cutaneous and ocular abnormalities, characteristic facies, renal, ectodermal, and temporal bone anomalies. Having determined that mutations involving TFAP2A result in BOFS, we studied a total of 30 families (41 affected individuals); 26/30 (87%) fulfilled our cardinal diagnostic criteria. The original family with the 3.2 Mb deletion including the TFAP2A gene remains the only BOFS family without the typical CL/P and the only family with a deletion. We have identified a hotspot region in the highly conserved exons 4 and 5 of TFAP2A that harbors missense mutations in 27/30 (90%) families. Several of these mutations are recurrent. Mosaicism was detected in one family. To date, genetic heterogeneity has not been observed. Although the cardinal criteria for BOFS have been based on the presence of each of the core defects, an affected family member or thymic remnant, we documented TFAP2A mutations in three (10%) probands in our series without a classic cervical cutaneous defect or ectopic thymus. Temporal bone anomalies were identified in 3/5 patients investigated. The occurrence of CL/P, premature graying, coloboma, heterochromia irides, and ectopic thymus, are evidence for BOFS as a neurocristopathy. Intrafamilial clinical variability can be marked. Although there does not appear to be mutation‐specific genotype–phenotype correlations at this time, more patients need to be studied. Clinical testing for TFAP2A mutations is now available and will assist geneticists in confirming the typical cases or excluding the diagnosis in atypical cases.
- 28 December 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 155 (1) , 22-32
Genotype–phenotype analysis of the branchio‐oculo‐facial syndrome
Branchio‐oculo‐facial syndrome (BOFS; OMIM#113620) is a rare autosomal dominant craniofacial disorder with variable expression. Major features include cutaneous and ocular abnormalities, characteristic facies, renal, ectodermal, and temporal bone anomalies. Having determined that mutations involving TFAP2A result in BOFS, we studied a total of 30 families (41 affected individuals); 26/30 (87%) fulfilled our cardinal diagnostic criteria. The original family with the 3.2 Mb deletion including the TFAP2A gene remains the only BOFS family without the typical CL/P and the only family with a deletion. We have identified a hotspot region in the highly conserved exons 4 and 5 of TFAP2A that harbors missense mutations in 27/30 (90%) families. Several of these mutations are recurrent. Mosaicism was detected in one family. To date, genetic heterogeneity has not been observed. Although the cardinal criteria for BOFS have been based on the presence of each of the core defects, an affected family member or thymic remnant, we documented TFAP2A mutations in three (10%) probands in our series without a classic cervical cutaneous defect or ectopic thymus. Temporal bone anomalies were identified in 3/5 patients investigated. The occurrence of CL/P, premature graying, coloboma, heterochromia irides, and ectopic thymus, are evidence for BOFS as a neurocristopathy. Intrafamilial clinical variability can be marked. Although there does not appear to be mutation‐specific genotype–phenotype correlations at this time, more patients need to be studied. Clinical testing for TFAP2A mutations is now available and will assist geneticists in confirming the typical cases or excluding the diagnosis in atypical cases.
- 24 November 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (12) , 3154-3156
Mosaic down syndrome in a patient with low‐level mosaicism detected by microarray
Down syndrome (DS) is the most common aneuploidy in liveborns with an estimated frequency of 1 in 650–1,000 births. Approximately 1–2% of all live‐born DS individuals have mosaicism. The correlation between the percentage of mosaicism and the severity of the phenotype in mosaic trisomy 21 has been determined in previous studies. Patients with low percent of trisomy 21 have less phenotypic manifestations, higher IQs, and better overall survival. We report on a 1‐day‐old baby girl with subtle features of DS and low‐level trisomy 21 mosaicism (8–13% in lymphocytes, 31% in buccal cells) with normal high resolution chromosome analysis. The aneuploidy was detected by 6.0 SNP microarray and confirmed by fluorescent in situ hybridization (FISH). Further studies to detect mosaicism are recommended from blood (using interphase FISH) or other tissues in the evaluation of a child with features of DS and a normal blood metaphase karyotype. SNP microarray technology appears to be a useful adjunct, being able to detect low‐level mosaicism in these cases.
- 24 November 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (12) , 3154-3156
Mosaic down syndrome in a patient with low‐level mosaicism detected by microarray
Down syndrome (DS) is the most common aneuploidy in liveborns with an estimated frequency of 1 in 650–1,000 births. Approximately 1–2% of all live‐born DS individuals have mosaicism. The correlation between the percentage of mosaicism and the severity of the phenotype in mosaic trisomy 21 has been determined in previous studies. Patients with low percent of trisomy 21 have less phenotypic manifestations, higher IQs, and better overall survival. We report on a 1‐day‐old baby girl with subtle features of DS and low‐level trisomy 21 mosaicism (8–13% in lymphocytes, 31% in buccal cells) with normal high resolution chromosome analysis. The aneuploidy was detected by 6.0 SNP microarray and confirmed by fluorescent in situ hybridization (FISH). Further studies to detect mosaicism are recommended from blood (using interphase FISH) or other tissues in the evaluation of a child with features of DS and a normal blood metaphase karyotype. SNP microarray technology appears to be a useful adjunct, being able to detect low‐level mosaicism in these cases.
- 20 July 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (8) , 2112-2114
A de novo balanced translocation breakpoint truncating the autism susceptibility candidate 2 (AUTS2) gene in a patient with autism
- 20 July 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (8) , 2112-2114
A de novo balanced translocation breakpoint truncating the autism susceptibility candidate 2 (AUTS2) gene in a patient with autism
- 25 January 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (2) , 498-503
A complex maternal rearrangement results in a pure 10.8 Mb duplication of the 5q13.1–q14.1 region in an affected son
- 25 January 2010
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 152A (2) , 498-503
A complex maternal rearrangement results in a pure 10.8 Mb duplication of the 5q13.1–q14.1 region in an affected son
- 28 October 2009
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 149A (11) , 2573-2577
Developmental disability and hypomelanosis of Ito in a female with 7.3 Mb de novo duplication of Xp11.3‐p11.4 and random X inactivation
- 28 October 2009
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 149A (11) , 2573-2577
Developmental disability and hypomelanosis of Ito in a female with 7.3 Mb de novo duplication of Xp11.3‐p11.4 and random X inactivation
- Open Access
- 2 September 2009
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 29 (35) , 10843-10854
A Neuroligin-4 Missense Mutation Associated with Autism Impairs Neuroligin-4 Folding and Endoplasmic Reticulum Export
Neuroligins (NLs) are postsynaptic cell-adhesion molecules essential for normal synapse function. Mutations in neuroligin-4 (NL4) (gene symbol:NLGN4) have been reported in some patients with autism spectrum disorder (ASD) and other neurodevelopmental impairments. However, the low frequency of NL4 mutations and the limited information about the affected patients and the functional consequences of their mutations cast doubt on the causal role of NL4 mutations in these disorders. Here, we describe two brothers with classical ASD who carry a single amino-acid substitution in NL4 (R87W). This substitution was absent from the brothers' asymptomatic parents, suggesting that it arose in the maternal germ line. R87 is conserved in all NL isoforms, and the R87W substitution is not observed in control individuals. At the protein level, the R87W substitution impaired glycosylation processing of NL4 expressed in HEK293 and COS cells, destabilized NL4, caused NL4 retention in the endoplasmic reticulum in non-neuronal cells and neurons, and blocked NL4 transport to the cell surface. As a result, the R87W substitution inactivated the synapse-formation activity of NL4 and abolished the functional effect of NL4 on synapse strength. Viewed together, these observations suggest that a point mutation in NL4 can cause ASD by a loss-of-function mechanism.
- 2 September 2009
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 29 (35) , 10843-10854
Open AccessA Neuroligin-4 Missense Mutation Associated with Autism Impairs Neuroligin-4 Folding and Endoplasmic Reticulum Export
Neuroligins (NLs) are postsynaptic cell-adhesion molecules essential for normal synapse function. Mutations in neuroligin-4 (NL4) (gene symbol:NLGN4) have been reported in some patients with autism spectrum disorder (ASD) and other neurodevelopmental impairments. However, the low frequency of NL4 mutations and the limited information about the affected patients and the functional consequences of their mutations cast doubt on the causal role of NL4 mutations in these disorders. Here, we describe two brothers with classical ASD who carry a single amino-acid substitution in NL4 (R87W). This substitution was absent from the brothers' asymptomatic parents, suggesting that it arose in the maternal germ line. R87 is conserved in all NL isoforms, and the R87W substitution is not observed in control individuals. At the protein level, the R87W substitution impaired glycosylation processing of NL4 expressed in HEK293 and COS cells, destabilized NL4, caused NL4 retention in the endoplasmic reticulum in non-neuronal cells and neurons, and blocked NL4 transport to the cell surface. As a result, the R87W substitution inactivated the synapse-formation activity of NL4 and abolished the functional effect of NL4 on synapse strength. Viewed together, these observations suggest that a point mutation in NL4 can cause ASD by a loss-of-function mechanism.
- Open Access
- 13 February 2009
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 84 (2) , 301
TFAP2A Mutations Result in Branchio-Oculo-Facial Syndrome
- 13 February 2009
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 84 (2) , 301
Open AccessTFAP2A Mutations Result in Branchio-Oculo-Facial Syndrome
- 1 May 2008
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 82 (5) , 1171-1177
TFAP2A Mutations Result in Branchio-Oculo-Facial Syndrome
- 1 May 2008
- Published by Elsevier in The American Journal of Human Genetics
- Vol. 82 (5) , 1171-1177
TFAP2A Mutations Result in Branchio-Oculo-Facial Syndrome
- 11 March 2008
- Published by Wiley in Clinical Genetics
- Vol. 73 (5) , 502-503
A re-examination of the chromosome 8p22-8p23.1 region in Kabuki syndrome
- 11 March 2008
- Published by Wiley in Clinical Genetics
- Vol. 73 (5) , 502-503
A re-examination of the chromosome 8p22-8p23.1 region in Kabuki syndrome